Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss
Authors:
- 20 October 2016
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 36 (11) , 1180-1184
Abstract
Purpose: To examine the risk of persistent sexual dysfunction (PSD) with finasteride 1 mg.Methods: We conducted a retrospective cohort study using the IMS U.S. health claims database. From an original cohort of 6,110,723 patients, we identified 1390 men who had stopped using finasteride 1 mg and 20,000 randomly selected age‐ and calendar time‐matched users of omeprazole from 2006 to 2014. First PSD event was defined as (1) the first PSD diagnosis through the first International Classification for Diseases, Ninth Revision, Clinical Modification) code for sexual dysfunction and (2) use of a phosphodiesterase inhibitor (sildenafil, tadalafil, or vardenafil).Results: In the primary analysis, we identified 1390 men taking finasteride 1 mg and 20,000 omeprazole users. The mean time to first PSD event after discontinuation of a finasteride 1 mg prescription was 391 days (SD, 357 days). The rate of PSD for finasteride 1 mg users and omeprazole users was 37.9 and 15.0 per 1000 person‐years, respectively. For the primary analysis of sexual dysfunction, the adjusted hazard ratio (HR) comparing finasteride 1 mg users to omeprazole users was 1.62 (1.14–2.29). Adjusted HR in the secondary analysis comparing finasteride users to omeprazole users with respect to the first phosphodiesterase inhibitor was 2.73 (2.01–3.69).Conclusions: The risk of PSD in men who stopped finasteride 1 mg therapy was higher than that for omeprazole users. Patients who stopped finasteride therapy sought physician visits for sexual dysfunction up to 1 year after stopping finasteride.Keywords
This publication has 14 references indexed in Scilit:
- Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopeciaInt. Journal of Clinical Pharmacology and Therapeutics, 2016
- Risperidone and Risk of Gynecomastia in Young MenJournal of Child and Adolescent Psychopharmacology, 2015
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Androgen Levels and Semen Parameters Among Former Users of Finasteride With Persistent Sexual Adverse EffectsJAMA Dermatology, 2014
- Persistent Sexual, Emotional, and Cognitive Impairment Post-FinasterideAmerican Journal of Men's Health, 2014
- Long-term Oral Administration of 5α-reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged RatsUrology, 2013
- Persistent Sexual Side Effects of Finasteride: Could They be Permanent?The Journal of Sexual Medicine, 2012
- 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The ConnectionThe Journal of Sexual Medicine, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Finasteride in the treatment of men with androgenetic alopeciaJournal of the American Academy of Dermatology, 1998